Evidence map›Paper›PMID 41586395›Full record

ArticleAnnals of gastroenterology

Interleukin 12/23 and interleukin 23 inhibitors for moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.

Bisher Sawaf, Mohammad Al Hayek, Ahmad Kassem, Dahham Alsoud, Mulham Alom, Abdelaziz H Salam, Rana H Shembesh, Mohammed S Beshr, Yusuf Hallak, Shahem Abbarh and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Bisher SawafInternal Medicine, University of Toledo, Toledo, OH, USA (Bisher Sawaf, Yusuf Hallak).
Mohammad Al HayekFaculty of Medicine, Damascus University, Damascus, Syrian Arab Republic (Mohammad Al Hayek).
Ahmad KassemDavid Geffen School of Medicine at UCLA, Los Angeles, California, USA (Ahmad Kassem).
Dahham AlsoudTranslational Research in Gastrointestinal Disorders, Department of Chronic Diseases and Metabolism, Katholieke Universiteit (KU) Leuven, Belgium (Dahham Alsoud).
Mulham AlomInternal Medicine, Southern Illinois University School of Medicine, Chicago, USA (Mulham Alom).
Abdelaziz H SalamHamidiye International School of Medicine, University of Health Sciences, Istanbul, Türkiye (Abdelaziz H. Salam).
Rana H ShembeshLibyan International Medical University, Faculty of Medicine, Benghazi, Libya (Rana H. Shembesh).
Mohammed S BeshrSana'a University, Faculty of Medicine and Health Sciences, Sana'a, Yemen (Mohammed S. Beshr).
Yusuf HallakInternal Medicine, University of Toledo, Toledo, OH, USA (Bisher Sawaf, Yusuf Hallak).
Shahem AbbarhInternal Medicine, MedStar Health Georgetown University, Baltimore, MD, USA (Shahem Abbarh).
Elias BatikhDepartment of Internal Medicine, John H Stroger Jr Hospital of Cook County, Chicago, IL, United States (Elias Batikh).
Mosa ShibaniGeneral Surgery Department, Glasgow Royal Infirmary, Glasgow, UK (Mosa Shibani).
Muhammed ElhadiCollege of Medicine, Korea University, Seoul, Republic of Korea (or South Korea) (Muhammed Elhadi).
Yaseen AlastalGastroenterology, University of Toledo, Toledo, OH, USA (Yaseen Alastal).
Miguel RegueiroDepartment of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH, USA (Miguel Regueiro).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ulcerative colitis (UC) is a chronic inflammatory disease affecting ~1.5 million individuals, causing significant impairment in quality of life, psychological well-being, and healthcare burden. Using indirect meta-analysis, this study compared the efficacy and safety of anti-interleukin (IL)-12/23 and IL-23 agents vs. placebo and each other, during induction and maintenance in moderate-to-severe UC. Methods: A systematic search of PubMed, Cochrane, Scopus, Web of Science, and ClinicalTrials. gov was conducted on October 1, 2024. The randomized controlled trials (RCTs) included evaluated ustekinumab, mirikizumab, risankizumab, and guselkumab. The primary outcomes were clinical remission and endoscopic improvement at both induction and maintenance endpoints. Odds ratios (ORs) with 95% confidence intervals (CIs) and surface under the cumulative ranking (SUCRA) values were used to rank treatment efficacy. Results: Six RCTs (n=3808) were analyzed for induction and 5 RCTs (n=1697) for maintenance. During induction, risankizumab demonstrated the highest clinical remission rates (OR 3.89, 95%CI 2.24-6.75; SUCRA 80.7%) and endoscopic improvement rates (OR 4.21, 95%CI 2.12-8.35; SUCRA 87.6%) compared to placebo. In maintenance, guselkumab showed the highest clinical remission (OR 4.28, 95%CI 1.58-11.59; SUCRA 81.6%) and endoscopic improvement (OR 4.21, 95%CI 2.12-8.35; SUCRA 93.1%), and was superior to risankizumab (OR 2.05, 95%CI 1.09-3.84) for endoscopic outcomes. Conclusions: Risankizumab was most effective in induction, while guselkumab was more effective in maintenance. Head-to-head trials are warranted.

Indexed as

interleukin-12/23 inhibitorsinterleukin-23 inhibitorsnetwork meta-analysissystematic reviewUlcerative colitis

Identifiers

PMID41586395
PMCPMC12829535

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.